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Summary
Background Expression of intrinsic markers of tumour hypoxia and angiogenesis are important predictors of 
radiotherapeutic, and possibly surgical, outcome in several cancers. Extent of tumour hypoxia in localised prostate 
cancer is comparable to that in other cancers, but few data exist on the association of extent of tumour hypoxia 
with treatment outcome. We aimed to study the predictive value of intrinsic markers of tumour hypoxia and angio-
genesis in localised prostate cancer, both in patients treated with radiotherapy and in those treated surgically.
Methods We applied a new, needle biopsy tissue microarray (TMA) technique to study diagnostic samples from 
men with localised, previously untreated prostate cancer treated in two randomised controlled trials of radiotherapy-
dose escalation. Multivariate analysis by Cox proportional hazards was done to assess the association between 
clinical outcome, in terms of biochemical control, and immunohistochemical staining of hypoxia inducible factor-
1 alpha (HIF-1 alpha), vascular endothelial growth factor (VEGF), and osteopontin expression. The analysis was 
repeated on an independent series of men with localised, previously untreated prostate cancer treated by radical 
prostatectomy. The main outcome was time to biochemical (ie, prostate-speciﬁ c antigen [PSA]) failure.
Findings Between Oct 12, 1995, and Feb 5, 2002, 308 patients were identiﬁ ed from two prospective, randomised 
trials at the Royal Marsden Hospital, London and Sutton, UK, for the radiotherapy cohort and diagnostic biopsies 
were available for 201 of these patients. Between June 6, 1995, and Nov 4, 2005, 329 patients were identiﬁ ed from 
the Aarhus University Hospital, Skejby, Denmark, for the prostatectomy cohort; of these, 40 patients were excluded 
because the tumour was too small to sample (19 patients), because the paraﬃ  n block was too thin (19 patients), or 
because the blocks were missing (two patients), leaving 289 patients for analysis. For patients treated with 
radiotherapy, increased staining for VEGF (p=0∙008) and HIF-1 alpha (p=0∙02) expression, but not increased 
osteopontin expression (p=0∙978), were signiﬁ cant predictors of a shorter time to biochemical failure on 
multivariate analysis, independent of clinical tumour stage, Gleason score, serum PSA concentration, and dose of 
radiotherapy. For patients treated with surgery, increased staining for VEGF (p<0∙0001) and HIF-1 alpha (p<0∙0001) 
expression, and increased osteopontin expression (p=0∙0005) were each signiﬁ cantly associated with a shorter 
time to biochemical failure on multivariate analysis, independent of pathological tumour stage, Gleason score, 
serum PSA concentration, and margin status.
Interpretation To our knowledge, this is the largest study of intrinsic markers of hypoxia and angiogenesis in 
relation to the outcome of radical treatment of localised prostate cancer. Increased expression of VEGF, HIF-1 
alpha, and, for patients treated with surgery, osteopontin, identiﬁ es patients at high risk of biochemical failure 
who would be suitable for enrolment into trials of treatment intensiﬁ cation. 
Funding Prostate Cancer Research Foundation, London, UK; Danish Cancer Society, Copenhagen, Denmark; Cancer 
Research UK, London, UK; and National Cancer Research Institute South of England Prostate Cancer Collaborative, 
London, UK.
Introduction 
Prostate cancer is the most commonly diagnosed cancer 
in men.1 Established prognostic factors, such as 
tumour (T) stage according to the tumour, nodes, 
metastases (TNM) staging system, Gleason score, and 
serum concentration of prostate-speciﬁ c antigen (PSA), 
are indicators of the natural history of disease2,3 and risk 
of recurrence after treatment.4 However, these factors 
explain only a moderate proportion of the variation in 
outcome, and there is an unmet need for better markers 
of prostate-cancer behaviour. Markers are needed to 
identify high-risk patients, for whom standard radical 
treatment has poor outcomes and who would be suitable 
for clinical trials of more aggressive treatments. 
Identiﬁ cation of such markers of prostate cancer 
behaviour might provide insight into the molecular 
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mechanisms underpinning disease progression, and 
therefore inform the search for new therapeutic 
targets.    
Hypoxia in human tumours has long been linked to 
radioresistance.5 Thomlinson and Gray6 ﬁ rst proposed 
the existence of hypoxia in human tumours more than 
50 years ago and described the radioresistance of 
hypoxic mammalian cells. Hypoxia has also been shown 
to be a potent stimulus for tumour progression, 
mediated via eﬀ ects on angiogenesis, genetic instability, 
glycolysis, inhibition of apoptosis, and upregulation of 
growth factors.7,8 In several cancers, including those of 
the head and neck,9,10 cervix,11 and soft-tissue sarcoma,12 
extent of tumour hypoxia is an important determinant 
of freedom from metastasis and overall survival. This 
ﬁ nding is very well-established for patients treated with 
radiotherapy, but is less certain for those treated with 
surgery alone.13 The importance of hypoxia and 
angiogenesis in tumour biology has been underlined by 
the proven eﬀ ectiveness of treatments that exploit these 
abnormalities.14,15    
A key eﬀ ect of hypoxia is the induction of gene 
expression mediated via hypoxia inducible factor 1 
alpha (HIF-1 alpha), a transcription factor that is 
stabilised under hypoxic conditions, and which induces 
a number of pathways important in tumour progression, 
such as angiogenesis, glycolysis, and proliferation.16 
Expression of HIF-1 alpha, assessed by immuno-
histochemistry, has been shown to predict radiotherapy 
outcome in several cancers.17,18 Transcription of the 
angiogenic factor vascular endothelial growth factor 
(VEGF) is directly controlled by HIF-1 alpha. Tissue 
expression of VEGF has been reported to predict 
treatment outcome in many cancers, including breast 
cancer,19 colorectal cancer,20 and osteosarcoma.21 
Osteopontin is a multifunctional secreted phospho-
glycoprotein that is also induced by hypoxia, and has 
been implicated in tumour development and 
metastasis.22 While its transcriptional regulation is not 
fully understood, osteopontin is known to be regulated 
by factors other than HIF-1 alpha.23 In head and neck 
cancer, tumour expression of osteopontin, assessed by 
immuno histochemistry, correlates signiﬁ cantly with 
tumour oxygenation measured by polarographic 
electrodes,24 and plasma osteopontin concentration is a 
predictor of radiotherapy outcome.10  
Extent of tumour hypoxia in localised prostate cancer 
has been shown to be comparable to that in other 
cancers,25 and HIF-1 alpha,26 VEGF,27 and osteopontin28 
are each overexpressed in prostate-cancer tissue in 
comparison with benign prostatic tissue. To our 
knowledge, no studies have assessed the association 
between HIF-1 alpha expression and prostate-cancer 
outcome. Three small clinical studies, with a combined 
total of 147 patients, have suggested that tumour hypoxia 
measured by use of polarographic electrodes,29 or 
immunohistochemical expression of VEGF30,31 are 
associated with treatment failure after radical treatment. 
Increased tumour-osteopontin expression was 
signiﬁ cantly associated with decreased survival in a 
study of 70 patients with prostate cancer.28 These 
considerations provide a rationale for more deﬁ nitive 
studies to assess the role of tumour hypoxia and 
angiogenesis in terms of the outcome of radical 
treatment for patients with localised prostate cancer. 
Our speciﬁ c aims were to identify a high-risk group of 
patients who would be suitable candidates for clinical 
trials of more aggressive treatment, and to test whether 
markers of hypoxia and angiogenesis were predictive of 
outcome in patients treated with radiotherapy and in 
patients treated surgically. The second aim is pertinent 
to localised prostate cancer, because, if hypoxia is a 
determinant of radiotherapeutic outcome, but not 
surgical outcome, assessment of tumour oxygenation 
in individual patients could inform the choice between 
these two treatment modalities.   
Methods
Patients and procedures
Radiotherapy cohort
Between Oct 12, 1995, and Feb 5, 2002, 308 patients 
with clinically localised or locally advanced (according 
to the TNM staging system: T1–3, N0 or Nx, M0 or Mx), 
histologically proven, previously untreated prostate 
cancer were treated with radical radiotherapy in one of 
two prospective, randomised dose-escalation trials32,33 
at the Royal Marsden Hospital, London and Sutton, 
UK. The randomised phase II dose-escalation pilot 
study (n=127) and the randomised phase III Medical 
Research Council RT01 trial (a trial of 843 patients of 
whom 181 patients were treated at the Royal Marsden 
Academic Urology Unit, London and Sutton, UK) were 
of almost identical design, and have been described 
elsewhere.32,33 Patients received 3–6 months of 
neoadjuvant androgen deprivation with subcutaneous 
goserelin 3∙6 mg or leuprorelin 3∙75 mg monthly, 
followed by radical radiotherapy to the prostate. 
Patients were randomly assigned to 64 Gy or 74 Gy 
radiotherapy in daily 2 Gy fractions. Patients were 
followed up with 6-monthly measurements of serum 
PSA concentration. No patient commenced salvage 
hormone treatment before PSA failure. All diagnostic 
samples underwent central pathological review by an 
experienced prostate cancer pathologist. Comprehensive 
clinical data were collected prospectively on a database 
in the Royal Marsden Academic Urology Unit. 
308 patients were eligible; for those who gave written 
informed consent and who had diagnostic biopsies, 
biopsy tissue microarray (TMA) was made by use of the 
checkerboard technique described by Jhavar and 
colleagues.34 This technique reorientates cancer tissue 
from needle-biopsy tissue vertically, rather than 
longitudinally, in paraﬃ  n blocks, thereby allowing 
many more sections to be taken for analysis. Initial 
Articles
344 http://oncology.thelancet.com   Vol 9   April 2008
sections (4 μm) cut on to Superfrost glass slides 
(Ultima, SuperFrost Ultra slides [LSL, Rochdale, UK]) 
were stained by haematoxylin and eosin to identify the 
location and morphology of tissue samples (ie, 
checkers) within the microarray block. The TMA 
included a total of 1164 tumour checkers, with a median 
of six checkers for each patient (range 4–21).
Radical prostatectomy cohort
Between June 6, 1995, and Nov 4, 2005, 329 men with 
histologically proven, previously untreated, clinically 
localised prostate cancer were treated by radical 
prostatectomy (RRP) at the Department of Urology, 
Aarhus University Hospital, Skejby, Denmark. Patients 
were followed up with 6-monthly measurements of 
serum PSA concentration. No patient commenced 
salvage hormone treatment before PSA failure. Data on 
clinicopathology, follow-up, and survival were available 
for all patients. A conventional TMA was constructed 
from tissue obtained at the time of surgery as described 
elsewhere.35 The most representative tumour areas 
were selected and marked on the haematoxylin and 
eosin-stained slides. By contrast to the TMA for the 
radiotherapy cohort described above, for each patient 
only a single core (diameter 0∙6 mm) was taken from 
the donor block with the tissue microarrayer (Beecher 
Instruments, Silver Spring, MD, USA). Sections of 
3 µm were cut on a microtome and transferred to glass 
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Figure 1:  Scoring of immunohistochemical staining
(A) HIF-1 alpha score 4 (×40). Stained with mouse monoclonal anti-HIF-1 alpha antibody (H1alpha67). (B) HIF-1 alpha score 1 (×20). (C) HIF-1 alpha score 0 (×40). 
(D) VEGF score 5 (×25). Stained with rabbit anti-VEGF polyclonal antibody (A-20 sc-152). (E) VEGF score 1 (×40). (F) VEGF score 0 (×40). (G) Osteopontin score 5 
(×40). Stained with anti-osteopontin rabbit aﬃ  nity isolated monoclonal antibody. (H) Osteopontin score 1 (×40). (I) Osteopontin score 0 (×40).
Radiotherapy (n=201) Radical prostatectomy (n=289)
Median age, years (range) 67 (50–80) 61 (45–78)
T stage*, n (%)
T1 38 (19) NA
T2 119 (59) 169 (59)
T3 44 (22)† 118 (41)
Gleason score, n (%)
<7 149 (74) 115 (40)
7 40 (20) 137 (48)
>7 12 (6) 35 (12)
Median initial PSA, ng/mL (range) 11·5 (1·0–145·0) 13·0 (1·9–211·0)
NA=not applicable. In the radical-prostatectomy group, two patients had missing pathological T stage and two 
patients had missing Gleason scores.*T stage is clinical for radiotherapy cohort and pathological for surgery cohort. 
†Includes one T4 patient in the radiotherapy cohort.
Table 1: Characteristics of patients 
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slides (Menzel-Gläser, SuperFrost Plus, Braunschweig, 
Germany).
Immunohistochemistry
The TMAs were sectioned, and immunohistochemical 
staining done for HIF-1 alpha, VEGF, and osteopontin. 
Staining for HIF-1 alpha was done by use of the mouse 
monoclonal anti-HIF-1 alpha antibody, H1alpha67 (Novus 
Biologicals, Littleton, CO, USA) at a dilution of 1:1000, 
according to the method described by Koukourakis and co-
workers.36 About 100 cancer cells were assessed for 
cytoplasmic HIF-1-alpha expression, and scored as: 
0=no staining; 1=less than 1% of cells; 2=1–10% of cells; 
3=10–50% of cells; and 4=more than 50% of cells (ﬁ gure 1).26 
HIF-1 alpha was assessed in terms of cytoplasmic, rather 
than nuclear, staining, in accordance with the method 
published by Zhong and colleagues,26 who reported that 
cytoplasmic staining was a better predictor of outcome. We 
did not assess nuclear staining of HIF-1 alpha. Colon 
adenocarcinoma tissue was used as a positive control. For 
patients who had intrapatient heterogeneity in scoring 
between diﬀ erent checkers, the worst score for each patient 
was used. Staining for VEGF was done by use of the rabbit 
anti-VEGF polyclonal antibody (A-20 sc-152; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) at a dilution of 
1 in 400, as described elsewhere.37 Healthy tonsil tissue was 
used as a positive control. Staining for osteopontin was 
done by use of the anti-osteopontin rabbit aﬃ  nity isolated 
Radiotherapy, n (%) Radical 
prostatectomy, n (%) 
HIF-1 alpha 201 285
0 0 24 (8)
1 6 (3) 132 (46)
2 52 (26) 96 (34)
3 89 (44) 23 (8)
4 54 (27) 10 (4)
VEGF 201 278
0 0 57 (21)
1 0 50 (18)
2 37 (18) 64 (23)
3 61 (30) 60 (22)
4 69 (34) 33 (12)
5 34 (17) 14 (5)
Osteopontin 201 285
0 0 14 (5)
1 4 (2) 27 (10)
2 62 (31) 56 (20)
3 85 (42) 81 (28)
4 45 (22) 93 (33)
5 5 (3) 14 (5)
Due to insuﬃ  cient tissue on the radical prostatectomy TMA section, VEGF was not 
assessed in 11 patients, HIF-1 alpha was not assessed in four patients, and 
osteopontin was not assessed in four patients. 
Table 2: Distribution of molecular marker expression 
Radiotherapy, n Hazard ratio (95% CI) p Radical 
prostatectomy, n 
Hazard ratio (95% CI) p
Initial PSA concentration, ng/mL 201 1·02 (1·01–1·03) <0·0001 289 1·01 (1·00–1·01) 0·023
Initial PSA concentration, ng/mL
<10 84 1 .. 87 1 ..
10–20 73 2·17 (1·20–3·94) 0·01 125 1·44 (0·81–2·55) 0·215
>20 44 5·29 (2·92–9·59) <0·0001 77 3·15 (1·80–5·52) <0·0001
T stage*
T1 38 1 .. .. .. ..
T2 119 1·17 (0·60–2·28) 0·65 169 1 ..
T3 44 2·51 (1·24–5·09) 0·01 118 2·57 (1·68–3·94) <0·0001
Gleason score
<7 149 1 .. 115 1 ..
7 40 1·36 (0·79–2·37) 0·269 137 3·13 (1·82–5·37) <0·0001
>7 12 4·01 (1·96–8·21) 0·0001 35 3·34 (1·69–6·62) 0·0005
Margin†
Positive .. .. .. 85 2·66 (1·75–4·04) <0·0001
Negative .. .. .. 198 1 ..
Radiotherapy dose, Gy 
64 103 1·73 (1·09-2·74) 0·02 .. .. ..
74 98 1 .. .. .. ..
HIF-1 alpha 201 1·79 (1·33–2·43) 0·0001 285 2·23 (1·84–2·71) <0·0001
VEGF 201 1·58 (1·24–2·00) 0·0002 278 1·75 (1·51–2·04) <0·0001
Osteopontin 201 1·49 (1·15–1·94) 0·003 285 1·68 (1·37–2·07) <0·0001
*T stage is clinical for radiotherapy cohort and pathological for surgery cohort. †Six patients had missing information on surgical-margin status.
Table 3: Univariate analysis of freedom from biochemical failure
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monoclonal antibody (Sigma, Gillingham, UK), at a dilution 
of 1 in 1000, according to the method described by Coppola.38 
Colon adenocarcinoma tissue was used as a positive control. 
Cytoplasmic staining for VEGF and osteopontin in up to 
100, and not less than 20, tumour cells was classiﬁ ed by use 
of a semiquantitative scoring method38,39 as: 0=no staining; 
1=less than 1% of cells; 2=1–10% of cells; 3=11–33% of cells; 
4=34–67% of cells; and 5=more than 67% of cells (ﬁ gure 1). 
Checkers with insuﬃ  cient numbers of identiﬁ able cancer 
cells were excluded. In patients who had intrapatient hetero-
geneity in scoring between diﬀ erent checkers, the worst 
score for each patient was used, based on the a-priori 
assumption that tumour behaviour would be more closely 
associated with the presence of highly hypoxic regions than 
with the average oxygenation. For all markers, experiments 
were repeated without the primary antibody as a negative 
control.
Scoring was done by a single expert prostate-cancer 
histopathologist (CMC), blinded to patient outcome. 
Only identiﬁ able adenocarcinoma with an appearance 
consistent with the Gleason grade previously attributed 
to the patient was scored. All areas of benign glands, 
equivocal areas, prostatic intraepithelial neoplasia, or 
stromal tissue, were not scored.
Statistical analysis
The main outcome measure was time to biochemical 
(PSA) failure. In the radiotherapy cohort, biochemical 
failure was deﬁ ned by use of the Houston criteria,40 
ie, an increase in serum PSA concentration of at least 
2 ng/mL greater than the nadir. In the surgical cohort, 
biochemical failure was deﬁ ned as a serum PSA 
concentration of more than 0∙2 ng/mL after radical 
prostatectomy. 
All analyses were done on the radiotherapy cohort 
alone, and then repeated on the surgical cohort alone. 
Correlations between clinical factors and molecular 
marker expression were done by use of Spearman’s 
correlation coeﬃ  cient. Univariate and multivariate 
analyses were done by use of Cox regression analysis. 
Patients free from biochemical failure were censored 
on the date of their last PSA test. In the multivariate 
analysis, a ﬁ xed baseline model was ﬁ rst constructed 
by use of known prognostic factors. These were Gleason 
score (<7, 7, or >7), T stage (T1, T2, or T3), and initial 
serum PSA concentration (continuous). For the 
radiotherapy cohort, clinical T stage was used, and the 
dose of radiotherapy (64 or 74 Gy) was also included in 
the ﬁ xed baseline model. For the surgical cohort, 
pathological T stage was used, and surgical margin 
status was also included in the ﬁ xed baseline model. 
Data on the postoperative serum PSA concentrations 
were unavailable, and so were not included in the 
model. Then, with the known prognostic factors forced 
into the model, the marker variables were entered in a 
stepwise manner. The analysis was repeated by use of 
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Figure 2: Freedom from biochemical failure (%) against time (years) with respect to expression of intrinsic markers of tumour hypoxia and angiogenesis*
(A) Radiotherapy cohort. (B) Radical prostatectomy cohort. *Marker categories pooled where fewer than ten patients in one category.
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the tissue-marker scores as discrete level factors rather 
than as continuous covariates. p values less than 0∙05 
were deemed statistically signiﬁ cant.
Role of the funding source
The Prostate Cancer Research Foundation, London, 
UK, contributed to funding of laboratory consumables. 
The Danish Cancer Society, Copenhagen, Denmark, 
contributed funding to tissue collection for the radical 
prostatectomy cohort. The sponsors had no role in 
study design, data collection, data analysis, data 
interpretation, writing of the report, or in the decision 
to submit for publication. RV, ARN, and CP had access 
to the raw data. CP had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results 
Of the 308 patients who were identiﬁ ed for the 
radiotherapy cohort, 248 patients gave written informed 
consent for their prostate biopsies and clinical 
information to be used in this study. Of these 
248 patients, diagnostic biopsies were available for 
201 patients and were used to make a biopsy TMA. For 
the 329 patients who were identiﬁ ed for the prostatec-
tomy cohort, 40 patients were excluded because the 
tumour was too small to sample (19 patients), because 
the paraﬃ  n block was too thin (19 patients), or because 
the blocks were missing (two patients), leaving 
289 patients for analysis.  
Table 1 shows characteristics of the patients. Median 
follow-up of the radiotherapy cohort was 7 years (range 
0–11), and 77 (38%) patients developed biochemical 
failure. 5-year freedom from biochemical failure in this 
cohort was 70∙4% (95% CI 63∙5–76∙3). Distribution of 
HIF-1 alpha, VEGF, and osteopontin expression is shown 
in table 2. Expression of all three markers was signiﬁ -
cantly correlated with the other two: VEGF and HIF-1 
alpha, r=0∙22, p=0∙002; VEGF and osteopontin, r=0∙32, 
p<0∙0001; osteopontin and HIF-1 alpha, r=0∙31, p<0∙0001. 
Signiﬁ cant correlations were noted between higher 
HIF-1 alpha expression and higher initial serum PSA 
concentration (p=0∙014), and between higher VEGF 
expression and higher Gleason score (p=0∙043). No 
signiﬁ cant correlation was noted between osteo pontin 
expression and any of the baseline clinical charac ter istics 
(T stage, Gleason score, and serum PSA concentration).
Radiotherapy Radical prostatectomy 
Hazard ratio 
(95% CI)
p Hazard ratio 
(95% CI)
p
Initial PSA 
concentration
1·02 
(1·01–1·03)
0·001 1·04 
(1·02–1·05)
<0·0001
T stage* 
T1 1 .. .. ..
T2 1·33 
(0·68–2·62)
0·406 1 ..
T3 2·19 
(1·04–4·60)
0·039 1·38 
(0·77–2·46)
0·282
Gleason score
<7 1 .. 1 ..
7 1·10 
(0·62–1·93)
0·750 2·48 
(1·43–4·30)
0·001
>7 2·15 
(0·91–5·05)
0·080 1·86 
(0·89–3·86)
0·097
Margin 
Positive .. .. 1·70 
(0·97–2·96)
0·061
Negative .. .. 1 ..
Radiotherapy 
dose, Gy 
64 1·95 
(1·21–3·15)
0·006 .. ..
74 1 .. .. ..
*T stage is clinical for radiotherapy cohort and pathological for surgery cohort.
Table 4: Baseline multivariate analysis of freedom from biochemical 
failure
Radiotherapy Radical prostatectomy
Hazard ratio 
(95% CI) 
p Hazard ratio 
(95% CI)
p
Initial PSA 
concentration
1·17 
(1·06–1·29)
0·002 1·01 
(0·99–1·03)
0·171
T stage* 
T1 1 .. .. ..
T2 1·37 
(0·69–2·71)
0·374 1 ..
T3 2·20 
(1·03–4·67)
0·041 1·33 
(0·78–2·29)
0·299
Gleason score
<7 1 .. 1 ..
7 0·99 
(0·54–1·81)
0·964 1·49 
(0·84–2·64)
0·172
>7 1·55 
(0·65–3·70)
0·328 1·36 
(0·61–3·03)
0·459
Margin 
Positive .. .. 1·79 
(1·06–3·04)
0·030
Negative .. .. 1 ..
Radiotherapy 
dose, Gy 
64 1·82 
(1·13–2·93)
0·014 .. ..
74 1 .. .. ..
HIF-1 alpha 1·46 
(1·05–2·04)
0·02 1·72 
(1·35–2·20)
<0·0001
VEGF 1·45 
(1·10–1·90)
0·008 1·45 
(1·23–1·72)
<0·0001
Osteopontin 1·00 
(0·74–1·36)
0·978 1·49 
(1·19–1·86)
0·0005
 *T stage is clinical for radiotherapy cohort and pathological for surgery cohort.
Table 5: Multivariate analysis of freedom from biochemical failure with 
expression of molecular markers included
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Univariate analysis of the radiotherapy cohort baseline 
factors in relation to biochemical control is shown in 
table 3. Increased expression of HIF-1 alpha (p=0∙0001), 
VEGF (p=0∙0002), and osteopontin (p=0∙003) were 
each signiﬁ cantly associated with decreased freedom 
from biochemical failure.  Figure 2 shows freedom 
from biochemical failure in terms of each of the 
immunohistochemical markers.
Multivariate analysis of the baseline clinical 
characteristics of the radiotherapy cohort in relation to 
biochemical control showed that high initial serum PSA 
concen tration (p=0∙001), high T stage (p=0∙039), and low 
radiotherapy dose (p=0∙006) were signiﬁ cant independent 
determin ants of decreased freedom from biochemical 
failure (table 4). Addition of the molecular markers to 
this baseline model showed that increased VEGF 
(p=0∙008) and HIF-1 alpha (p=0∙02) expression, but not 
osteopontin expression (p=0∙978), were each signiﬁ cant 
determinants of decreased freedom from biochemical 
failure, independent of clinical characteristics (table 5). 
Analysis of the marker scores as discrete level factors, 
rather than as continuous covariates, gave similar 
ﬁ ndings (data not shown).
Median follow-up of the radical prostatectomy cohort 
was 2 years (range 0–7), and 91 (32%) of the 289 patients 
developed biochemical failure. 3-year freedom from 
biochemical failure was 60∙6% (95% CI 52∙9–67∙4). 
The distribution of HIF-1 alpha, VEGF, and osteopontin 
expression is shown in table 2. Expression of VEGF and 
HIF-1 alpha were signiﬁ cantly correlated with each 
other (r=0∙34, p<0∙0001), but not with osteopontin 
expression. Higher expression of HIF-1 alpha was 
signiﬁ cantly correlated with higher pathological T stage 
(p=0∙001) and higher initial serum PSA concentration 
(p=0∙01). A signiﬁ cant correlation with higher VEGF 
expression was noted for higher pathological T stage 
(p=0∙009) and higher Gleason score (p=0∙038). Higher 
osteopontin expression was correlated with higher 
Gleason score (p=0∙024). 
Univariate analysis of the baseline factors of the 
radical prostatectomy cohort in relation to biochemical 
control is shown in table 3. Increased expression of 
HIF-1 alpha (p<0∙0001), VEGF (p<0∙0001), and 
osteopontin (p<0∙0001) were each signiﬁ cantly 
associated with decreased freedom from biochemical 
failure. Figure 2 shows freedom from biochemical 
failure in terms of each of the molecular markers.
Multivariate analysis of the baseline clinical 
characteristics of the radical prostatectomy cohort in 
relation to biochemical control showed that initial 
serum PSA concentration (p<0∙0001), and higher 
Gleason score (p=0∙001) were signiﬁ cant independent 
determin ants of decreased freedom from biochemical 
failure (table 4). On multivariate analysis that incor-
porated the baseline clinical characteristics and 
increased expression of all three molecular markers, 
VEGF (p<0∙0001), HIF-1 alpha (p<0∙0001), and 
osteopontin (p=0∙0005) was signiﬁ cantly associated 
with decreased freedom from biochemical failure 
(table 5). Analysis of the marker scores as discrete level 
factors, rather than as continuous covariates, gave 
similar ﬁ ndings (data not shown).
Discussion
To our knowledge, this is the largest study of intrinsic 
markers of hypoxia and angiogenesis in relation to the 
outcome of radical treatment of localised prostate 
cancer. Increased expression of HIF-1 alpha and VEGF 
were each signiﬁ cant predictors of worse freedom from 
biochemical failure, independent of T stage, Gleason 
score, initial PSA concentration, and each other. These 
ﬁ ndings were consistent for patients treated with radical 
radiotherapy and for those treated with radical 
prostatectomy. Additionally, increased osteopontin 
expression was a signiﬁ cant, independent determinant 
of worse treatment outcome for surgically treated 
patients, but not for those who underwent 
radiotherapy.
These ﬁ ndings are consistent with the data available 
on the role of tumour hypoxia and angiogenesis in 
progression of prostate cancer. A polarographic 
electrode study29 of 57 patients with localised disease 
treated with brachytherapy showed a signiﬁ cant 
association between tumour oxygenation and time to 
biochemical recurrence; however, that study had only 
nine failure events for analysis. The expression of VEGF 
in prostate cancer is associated with the extent of 
tumour hypoxia,39 and in a study of 50 patients with 
locally advanced disease treated with radical 
radiotherapy, Green and co-workers30 reported a 
correlation between higher VEGF expression and worse 
disease-speciﬁ c survival (p=0∙035). Furthermore, in a 
study31 that compared 17 patients who developed bone 
metastases after radical prostatectomy with 23 patients 
who remained disease-free, expression of VEGF-A was 
signiﬁ cantly higher in those who developed bone 
metastases after radical prostatectomy. Higher plasma 
concentrations of VEGF have also been associated with 
biochemical progression after radical prostatectomy.41 
The concentration of osteopontin in serum is associated 
with tumour hypoxia,42 and, in a study of 90 patients 
with prostate cancer, increased serum osteopontin 
concentration was associated with higher Gleason 
score, presence of bone metastases, and increased 
disease-speciﬁ c mortality.43 Several studies,44,45 although 
not all,46 have shown an association between microvessel 
density—a measure of angiogenesis—and outcome in 
patients with prostate cancer. 
The ﬁ nding that molecular markers of tumour 
hypoxia and angiogenesis predict treatment outcome in 
patients with localised prostate cancer has several 
potentially important implications. First, there is a need 
for markers to identify high-risk patients, for whom 
standard radical treatment has poor outcomes, who 
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would be suitable for clinical trials of more aggressive 
treatment. Analysis of expression of HIF-1 alpha, VEGF, 
and osteopontin in diagnostic biopsies by use of simple 
widely available immuno histochemical techniques 
used in addition to the conventional risk factors of 
serum PSA concentration, T stage, and Gleason score, 
could identify such a high-risk group. Conﬁ rmatory 
studies that focus on patients with intermediate-risk 
disease according to conventional criteria are needed. 
Ideally, these studies should have long-term follow-up 
to enable analysis of local recurrence and distant 
metastases, besides biochemical failure. Second, 
prognostic markers need to distinguish between 
patients who need radical treatment and those who 
could be monitored safely without intervention. Further 
studies are warranted of mature cohorts managed by 
watchful waiting to assess whether HIF-1 alpha, VEGF, 
and osteopontin could improve our ability to identify 
indolent prostate cancer. Third, our ﬁ ndings might be 
relevant to the search for new therapeutic targets in 
localised prostate cancer. The association we recorded 
between treatment outcome and expression of HIF-1 
alpha, VEGF, and osteopontin, raises the possibility 
that these markers, or other components of the hypoxia–
angiogenesis axis, could represent valid therapeutic 
targets. Androgen deprivation has been shown to 
decrease angiogenesis in prostate cancer in animals,47 
and improve tumour oxygenation in patients with 
prostate cancer,48 making adjuvant hormone treatment 
a promising option for study in this group. Subgroup 
analysis of completed randomised controlled trials of 
adjuvant hormone treatment in terms of expression of 
HIF-1 alpha, VEGF, and osteopontin is needed. The 
beneﬁ ts of adjuvant hormonal treatment might be 
greater in those patients with increased expression of 
tissue markers of hypoxia and angiogenesis at baseline. 
Additionally, taken together with evidence of beneﬁ t 
from drugs that target hypoxia and proangiogenic 
proteins in other tumour types,14,15,49,50 our ﬁ ndings 
strengthen the rationale for trials of such drugs in 
patients with high-risk localised prostate cancer.  
Conventional TMAs have proved useful in high-
throughput assessment of prognostic markers in 
patients with prostate cancer.51 However, the 
conventional technique is restricted to resection 
specimens (radical prostatectomy or transurethral 
resection of the prostate). By use of the technique 
described by Jhavar and colleagues, we used TMAs 
constructed from specimens from diagnostic needle 
biopsies, which enabled TMA technology to be applied 
for the ﬁ rst time, to our knowledge, to patients managed 
by radiotherapy. This study conﬁ rms the feasibility and 
use of this technique, which should now be applied to 
other candidate markers and to tissue samples from 
other prospective trials of prostate cancer radiotherapy. 
The same technique could also be applied to patients 
managed by active surveillance—for whom diagnostic 
biopsies are typically the only tissue available—to 
identify markers that distinguish between patients that 
need radical treatment and those that could be safely 
monitored. 
A strength of this study is the replication of the main 
ﬁ ndings in two independent cohorts, one treated with 
radiotherapy and the other treated with surgery. The fact 
that the tissue markers were associated with outcome in 
two very diﬀ erent settings suggests that the markers 
will probably be useful in clinical practice. The 
observation also lends support to the view that tumour 
hypoxia does not just cause radioresistance, but is also 
associated with an aggressive tumour phenotype.7,8 The 
study also has some limitations: ﬁ rst, the duration of 
follow-up was relatively short, and there were insuﬃ  cient 
clinical failure events for analysis. The main outcome 
measure, biochemical failure, has not been shown to be 
a surrogate for clinically meaningful endpoints, such as 
prostate-cancer mortality. However, biochemical failure 
is a major concern to patients who have increased serum 
PSA concentrations because it leads to the morbidity 
associated with salvage treatment, and patients with 
biochemical failure are at signiﬁ cant risk of death from 
prostate cancer;52 second, although, to our knowledge, 
this is the largest study of its kind, the 201 patients who 
had radiotherapy might not have been representative of 
the 308 patients from which they were taken, and 
analysis of the radiotherapy cohort was not adequately 
powered to detect any interaction between marker 
expression and radiotherapy dose with respect to 
treatment outcome. Further studies will be needed to 
address this important issue and to assess the predictive 
role of expression of HIF-1 alpha, VEGF, and osteopontin 
in patients treated with radiotherapy alone without 
neoadjuvant androgen deprivation. Given that androgen 
deprivation improves tumour oxygenation,48 these 
markers might be even more important in patients 
treated with radiotherapy alone. Third, unlike the biopsy 
TMA from the radiotherapy cohort, the TMA from the 
radical prostatectomy cohort included only a single core 
from each patient. Due to the possibility of intrapatient 
heterogeneity of tissue-marker expression, this 
limitation could only have weakened any association 
between marker expression and outcome in the surgical 
cohort. Fourth, we noted a signiﬁ cant diﬀ erence in the 
distribution of marker expression between the 
radiotherapy and the surgical cohorts, for which the 
explanation is uncertain. Undoubtedly, the single core 
per patient on the TMA from the surgical cohort, by 
contrast with a median of six checkers per patient on the 
TMA from the radiotherapy cohort, would have 
contributed to this observation. Other possible factors 
include an eﬀ ect of the age of the specimens, or of 
general anaesthesia during surgery, on staining for 
marker expression. Last, the associations noted between 
clinical outcome and staining for HIF-1 alpha, VEGF, 
and osteopontin are not suﬃ  cient to conclude that 
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tumour hypoxia and angiogenesis adversely aﬀ ect 
treatment eﬃ  cacy, and that these markers constitute 
therapeutic targets. Staining for HIF-1 alpha, VEGF, 
and osteopontin might only serve as a marker for an 
aggressive tumour phenotype.
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